Phio Pharmaceuticals Corp. PHIO 深 沪
等待开盘 02-06 09:30:00 美东时间
0.8568
-0.068
-7.37%
华盛通- 最 高0.916
- 今 开0.91
- 成交量 42.34万股
- 最 低 0.8127
- 昨 收 0.925
- 总市值 922.30万
- 52周最高 4.1899
- 市盈率 静 --
- 换手率 3.93%
- 52周最低 0.8127
- 委 比 94.17%
- 总股本 1076.44万
- 历史最高 3118.50
- 量 比 1.76
- 振 幅 11.17%
- 历史最低 0.8127
- 每 手 1
- 风险率 0.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Phio Pharmaceuticals Data From Phase 1b Dose Escalation Clinical Study Shows 14 Participants To Be Pathologic Responders, Including 10 With 100% Clearance
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced
01-20 22:35
Phio Pharmaceuticals' Nonclinical Protocol For PH-762 Accepted By FDA; Toxicology Study Set To Begin In Q1 2026 Following Phase 1b Skin Cancer Results
Nonclinical protocol study design accepted by FDAStudy to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage
2025-12-23 21:47
Phio Pharma Q3 EPS $(0.44) Misses $(0.40) Estimate
Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.40) by 10 percent. This is a 71.43 percent increase over losses of $(1.54) per share from the
2025-11-14 05:23
Phio Pharma Secures $13.4M Through Warrant Exercises Covering 5.66M Shares, Including Reduced $2.05 Pricing On 4.65M Shares
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the
2025-11-04 03:02
Why Is Phio Pharmaceuticals Stock Soaring Today?
Shares of Phio Pharmaceuticals Corp. (NASDAQ: PHIO) are rising Monday after the company provided an update on an ongoing medical trial.
2025-11-04 02:25
Phio Pharma Reports 100% Tumor Clearance In Final Dose Group Of Skin Cancer Trial
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today
2025-11-03 20:49
Phio Pharma To Present PH-762 INTASYL siRNA Skin Cancer Trial Progress And Strategic Outlook At Life Sciences Future Conference Sept. 25-26, 2025
Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp.
2025-09-18 19:48
Phio Pharmaceuticals Stockholders Approve Key 2025 Proposals
The latest announcement is out from Phio Pharmaceuticals ( ($PHIO) ). At the An...
2025-09-16 04:39
Phio Pharmaceuticals to Attend Global Investment Conference
The latest announcement is out from Phio Pharmaceuticals ( ($PHIO) ). On Septem...
2025-09-03 20:28
HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $14 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price target.
2025-08-15 19:17
